Drug Profile
Motavizumab
Alternative Names: MEDI-524; Numax; RezieldLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 16 Oct 2020 Discontinued - Phase-II for Respiratory syncytial virus infections (In adolescents, In children, In infants, Prevention) in Belgium, Czech Republic, Denmark, Germany, Hungary, Spain, Sweden, United Kingdom, Austria (IM)
- 16 Oct 2020 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants) in Australia (IV)
- 16 Oct 2020 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants) in Chile (IV)